Garnier FJC, Pizarro AG, Orozco GR

Language: Spanish
References: 18
Page: 1-10
PDF size: 207.17 Kb.

ABSTRACT

Peripartum cardiomyopathy is defined as: acute heart failure secondary to systolic dysfunction, occurring towards the end of pregnancy or in the first five months after delivery. It has an incidence of 1 in 1,000 to 1 in 4,000 births.
The most important risk factor is being of African descendence; other factors are advanced maternal age, multiparity and hypertensive disorders. The pathophysiology remains unknown, and autoimmune processes, inflammatory factors, acute infections, malnutrition, hormonal alterations, cellular apoptosis, endothelial dysfunction and oxidative stress have been proposed as the causes of the disease.
The clinical manifestations are varied and include fatigue, exertional dyspnea, paroxysmal nocturnal dyspnea, cough, orthopnea, edema with pitting, palpitations, chest pain, tachypnea, tachycardia, elevated jugular venous pressure, pulmonary rales, gallop rhythm and ascites. The diagnosis is of exclusion, and an echocardiogram, electrocardiogram, measurement of natriuretic peptides (BNP and NT pro-BNP), and chest X-ray should be requested.
Treatment is like other causes of heart failure and includes maintaining adequate oxygenation, fluid and salt restriction, and slowing the progression of left ventricular dysfunction. The drugs used are diuretics, vasodilators, inotropics, angiotensin converting enzyme inhibitors, angiotensin receptor II inhibitors, beta-blockers, digoxin, spironolactone and anticoagulation with heparin. Mortality is approximately 4%.

REFERENCES

1. Azibani F, Sliwa K. Peripartum Cardiomyopathy: An Update. Curr Heart Fail Rep. octubre de 2018;15(5):297-306.

2. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy. J Am Coll Cardiol. enero de 2020;75(2):207-21.

3. Asad ZUA, Maiwand M, Farah F, Dasari TW. Peripartum cardiomyopathy: A systematic review of the literature. Clin Cardiol. mayo de 2018;41(5):693-7.

4. Cunningham FG, Byrne JJ, Nelson DB. Peripartum Cardiomyopathy. Obstet Gynecol. enero de 2019;133(1):167-79.

5. Arany Z. Understanding Peripartum Cardiomyopathy. 2017;12.

6. Bauersachs J, König T, Meer P, Petrie MC, Hilfiker‐Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. julio de 2019;21(7):827-43.

7. Cruz MO, Briller J, Hibbard JU. New Insights in Peripartum Cardiomyopathy. Obstet Gynecol Clin North Am. junio de 2018;45(2):281-98.

8. Koenig T, Hilfiker-Kleiner D, Bauersachs J. Peripartum cardiomyopathy. Herz. agosto de 2018;43(5):431-7.

9. Durán-Morales MA, Ariza-Parra EJ. Miocardiopatía periparto: patología potencialmente mortal. :9.

10. Auger N, Ukah UV, Potter BJ. Peripartum cardiomyopathy: a family affair? Heart. julio de 2019;105(14):1051-2.

11. Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ. 30 de enero de 2019;k5287.

12. Thompson L, Hartsilver E. Peripartum cardiomyopathy. 2016;31:4.

13. Jagodzińska A, Gondek A, Pietrzak B, Cudnoch-Jędrzejewska A, Mamcarz A, Wielgoś M. Peripartum cardiomyopathy – from pathogenesis to treatment. :9.

14. Baris L, Cornette J, Johnson MR, Sliwa K, Roos-Hesselink JW. Peripartum cardiomyopathy: disease or syndrome? :6.

15. Zagelbaum NK, Bhinder J, Gupta CA, Frishman WH, Aronow WS. Peripartum Cardiomyopathy Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology, and Treatment Options. Cardiol Rev. mayo de 2020;28(3):148-55.

16. Torga JEP, Rubio PAR, García I, Ramírez NMS, Arocha IC, Boffil P. Peripartum Cardiomyopathy. :15.

17. Goland S, Elkayam U. Peripartum cardiomyopathy: approach to management. 2018;33(00):7.

18. Gupta D, Wenger NK. Peripartum cardiomyopathy: Status 2018. Clin Cardiol. febrero de 2018;41(2):217-9.